Biodexa Pharmaceuticals (BDRX) Short Interest Ratio & Short Volume $7.04 +0.13 (+1.88%) Closing price 03:58 PM EasternExtended Trading$7.00 -0.04 (-0.57%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock Biodexa Pharmaceuticals Short Interest DataBiodexa Pharmaceuticals (BDRX) has a short interest of 18,000 shares, representing 0.49% of the float (the number of shares available for trading by the public). This marks a -95.06% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 36,775 shares to cover all short positions.Current Short Interest18,000 sharesPrevious Short Interest364,700 sharesChange Vs. Previous Month-95.06%Dollar Volume Sold Short$141.30 thousandShort Interest Ratio0.1 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares3,650,000 sharesShort Percent of Float0.49%Today's Trading Volume10,544 sharesAverage Trading Volume36,775 sharesToday's Volume Vs. Average29% Short Selling Biodexa Pharmaceuticals? Sign up to receive the latest short interest report for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBDRX Short Interest Over TimeBDRX Days to Cover Over TimeBDRX Percentage of Float Shorted Over Time Biodexa Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202518,000 shares $141.30 thousand -95.1%0.5%0.1 $7.85 7/15/2025364,700 shares $3.21 million +91.6%N/A0.1 $8.80 6/30/2025190,300 shares $164.61 thousand +6.9%0.5%0.1 $0.87 6/15/2025178,000 shares $190.46 thousand -51.5%0.5%0.1 $1.07 5/31/2025366,900 shares $395.63 thousand +93.5%1.0%0.1 $1.08 5/15/2025189,600 shares $246.48 thousand -16.8%0.5%0.1 $1.30 4/30/2025228,000 shares $332.88 thousand -21.4%N/A0.1 $1.46 4/15/2025290,200 shares $423.69 thousand +323.7%0.8%0.2 $1.46 3/31/202568,500 shares $90.42 thousand +10.3%0.2%0 $1.32 3/15/202562,100 shares $117.99 thousand +72.0%0.2%0 $1.90 Get the Latest News and Ratings for BDRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/202536,100 shares $120.21 thousand -23.2%0.1%0 $3.33 2/15/202547,000 shares $200.69 thousand +1,368.8%0.1%0.1 $4.27 1/31/20253,200 shares $14.11 thousand -50.8%N/A0 $4.41 1/15/20256,500 shares $27.79 thousand -37.5%N/A0 $4.28 12/31/202410,400 shares $42.12 thousand -62.6%N/A0 $4.05 12/15/202427,800 shares $116.76 thousand -46.5%N/A0.1 $4.20 11/30/202452,000 shares $292.24 thousand +225.0%N/A0.2 $5.62 11/15/202416,000 shares $57.92 thousand +15.9%N/A0.1 $3.62 10/31/202413,800 shares $84.87 thousand -50.2%N/A0.1 $6.15 10/15/202427,700 shares $138.78 thousand +108.3%N/A0.2 $5.01 9/30/202413,300 shares $3.75 thousand -83.7%N/A0.2 $0.28 9/15/202481,400 shares $33.54 thousand -5.2%N/A0.1 $0.41 8/31/202485,900 shares $47.25 thousand -17.7%N/A0.1 $0.55 8/15/2024104,400 shares $63.13 thousand +63.4%N/A0.1 $0.60 7/31/202463,900 shares $44.09 thousand -89.2%N/A0 $0.69 7/15/2024589,700 shares $572.01 thousand +318.5%N/A0.1 $0.97 6/30/2024140,900 shares $126.23 thousand -35.6%N/A0 $0.90 6/15/2024218,800 shares $214.64 thousand -34.6%N/A0 $0.98 5/31/2024334,700 shares $322.78 thousand +3.9%N/A0.1 $0.96 5/15/2024322,000 shares $363.86 thousand -84.4%N/A0.1 $1.13 4/30/20242,060,000 shares $3.11 million +986.5%N/A0.6 $1.51 4/15/2024189,600 shares $157.97 thousand +183.8%N/A0.1 $0.83 3/31/202466,800 shares $108.22 thousand -34.9%N/A0 $1.62 3/15/2024102,600 shares $120.04 thousand -32.3%N/A0.2 $1.17 2/29/2024151,600 shares $192.53 thousand -37.1%N/A0.3 $1.27 2/15/2024241,100 shares $383.35 thousand +414.1%N/A0.2 $1.59 1/31/202446,900 shares $75.51 thousand +3.3%N/A0.1 $1.61 1/15/202445,400 shares $91.25 thousand -46.7%N/A0.1 $2.01 12/31/202385,100 shares $228.07 thousand -51.8%N/A0.1 $2.68 12/15/2023176,500 shares $524.21 thousand -43.3%N/A0.3 $2.97When the levee breaks (Ad)The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.Click here to watch the urgent broadcast and get ahead of what’s coming. 11/30/2023311,300 shares $1.13 million +3,044.4%N/A0.5 $3.62 11/15/20239,900 shares $25.34 thousand -5.7%N/A0 $2.56 10/31/202310,500 shares $39.69 thousand -61.5%N/A0 $3.78 10/15/202327,300 shares $132.13 thousand +875.0%N/A0.1 $4.84 9/30/20232,800 shares $13.97 thousand -63.6%N/A0 $4.99 9/15/20237,700 shares $47.59 thousand -64.2%N/A0 $6.18 8/31/202321,500 shares $171.79 thousand -28.3%N/A0 $7.99 8/15/202330,000 shares $148.80 thousand -50.3%N/A0.1 $4.96 7/31/202360,300 shares $328.64 thousand -27.1%N/A0.1 $5.45 7/15/202382,700 shares $445.75 thousand +100.2%N/A0.3 $5.39 6/30/202341,300 shares $226.65 thousand -85.5%N/A0.3 $5.49 6/15/2023284,600 shares $22.14 thousand +156.2%N/A0.1 $0.08 5/31/2023111,100 shares $9.33 thousand -37.8%N/A0 $0.08 5/15/2023178,700 shares $40.48 thousand No ChangeN/A0.1 $0.23 3/15/202384,900 shares $118.86 thousand +41.7%N/A1.6 $1.40 2/28/202359,900 shares $31.15 thousand +0.5%N/A1.2 $0.52 2/15/202359,600 shares $37.55 thousand +111.4%N/A1.3 $0.63 1/31/202328,200 shares $19.74 thousand +18.0%N/A0.7 $0.70 1/15/202323,900 shares $15.54 thousand -38.2%N/A0.8 $0.65 12/30/202238,700 shares $38.12 thousand +26.9%N/A2 $0.99 12/15/202230,500 shares $24.40 thousand +254.7%N/A1.7 $0.80 11/30/20228,600 shares $13.67 thousand -1.2%N/A0.4 $1.59 11/15/20228,700 shares $13.89 thousand +6.1%N/A0.4 $1.60 10/31/20228,200 shares $15.91 thousand +310.0%N/A0.3 $1.94 10/15/20222,000 shares $3.85 thousand -39.4%N/A0.1 $1.92 9/30/20223,300 shares $6.14 thousand -61.6%N/A0.1 $1.86 9/15/20228,600 shares $28.64 thousand -74.2%N/A0.4 $3.33 8/31/202233,300 shares $24.64 thousand +69.0%N/A0.7 $0.74 8/15/202219,700 shares $14.68 thousand -63.3%N/A0.1 $0.75 7/31/202253,700 shares $35.17 thousand +47.9%N/A0.3 $0.65 7/15/202236,300 shares $26.14 thousand -44.8%N/A0.2 $0.72 6/30/202265,800 shares $35.53 thousand -24.2%N/A0.3 $0.54 6/15/202286,800 shares $44.94 thousand +617.4%N/A0.4 $0.52 5/31/202212,100 shares $7.58 thousand -28.8%N/A0.1 $0.63 5/15/202217,000 shares $8.92 thousand +794.7%N/A0.3 $0.52 4/30/20221,900 shares $1.24 thousand -93.7%N/A0 $0.65 4/15/202230,100 shares $25.89 thousand -28.8%N/A0.5 $0.86 3/31/202242,300 shares $37.22 thousand +6.0%N/A0.7 $0.88 3/15/202239,900 shares $32.95 thousand +17.0%N/A0.5 $0.83 2/28/202234,100 shares $33.45 thousand -55.3%N/A0.3 $0.98 2/15/202276,300 shares $76.07 thousand +149.4%N/A0.6 $1.00 1/31/202230,600 shares $30.91 thousand -42.8%N/A0.2 $1.01 1/15/202253,500 shares $60.46 thousand +59.7%N/A0.4 $1.13 12/31/202133,500 shares $35.18 thousand -83.7%N/A0.2 $1.05 12/15/2021205,800 shares $234.61 thousand +53.5%N/A1.6 $1.14 11/30/2021134,100 shares $195.79 thousand +9.2%N/A1.4 $1.46 11/15/2021122,800 shares $200.16 thousand -31.3%N/A1.2 $1.63 10/29/2021178,700 shares $303.79 thousand +19.1%N/A1.8 $1.70 10/15/2021150,000 shares $255.75 thousand +1.6%N/A1.4 $1.71 9/30/2021147,600 shares $256.82 thousand -12.4%N/A1.2 $1.74When the levee breaks (Ad)The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.Click here to watch the urgent broadcast and get ahead of what’s coming. 9/15/2021168,500 shares $291.51 thousand +1.9%N/A1.1 $1.73 8/31/2021165,400 shares $302.68 thousand -34.0%N/A0.1 $1.83 8/13/2021250,600 shares $455.32 thousand -9.4%N/A0.1 $1.82 7/30/2021276,700 shares $514.66 thousand +0.8%N/A0.1 $1.86 7/15/2021274,600 shares $503.89 thousand -18.0%N/A0.1 $1.84 6/30/2021334,700 shares $696.18 thousand +102.2%N/A0.2 $2.08 6/15/2021165,500 shares $331 thousand No ChangeN/A0.1 $2.00 5/28/2021165,500 shares $316.11 thousand -7.9%N/A0.7 $1.91 5/14/2021179,700 shares $359.40 thousand +10.5%N/A0.6 $2.00 4/30/2021162,600 shares $320.32 thousand +7.4%N/A0.4 $1.97 4/15/2021151,400 shares $307.34 thousand -15.7%N/A0.2 $2.03 3/31/2021179,500 shares $384.13 thousand +7.1%N/A0.2 $2.14 3/15/2021167,600 shares $398.89 thousand -13.8%N/A0.2 $2.38 2/26/2021194,400 shares $480.17 thousand -5.6%N/A0.2 $2.47 2/12/2021206,000 shares $585.04 thousand +89.3%N/A0.2 $2.84 1/29/2021108,800 shares $233.92 thousand +1.2%N/A0.1 $2.15 1/15/2021107,500 shares $245.10 thousand -36.1%N/A0.3 $2.28 12/31/2020168,200 shares $319.58 thousand +43.5%N/A0.4 $1.90 12/15/2020117,200 shares $227.50 thousand +2.5%N/A0.3 $1.94 11/30/2020114,400 shares $208.21 thousand -16.3%N/A0.3 $1.82 11/15/2020136,600 shares $260.91 thousand -12.1%N/A0.4 $1.91 10/30/2020155,400 shares $289.04 thousand +50.0%N/A0 $1.86 10/15/2020103,600 shares $198.91 thousand -3.6%N/A0 $1.92 9/30/2020107,500 shares $194.58 thousand -7.7%N/A0 $1.81 9/15/2020116,500 shares $228.34 thousand -48.7%N/A0 $1.96 8/31/2020227,100 shares $526.87 thousand +4,731.9%N/A0 $2.32 8/14/20204,700 shares $12.78 thousand -99.6%N/A0 $2.72 BDRX Short Interest - Frequently Asked Questions What is Biodexa Pharmaceuticals' current short interest? Short interest is the volume of Biodexa Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 18,000 shares of BDRX short. 0.49% of Biodexa Pharmaceuticals' shares are currently sold short. Learn More on Biodexa Pharmaceuticals' current short interest. What is a good short interest percentage for Biodexa Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.49% of Biodexa Pharmaceuticals' floating shares are currently sold short. Is Biodexa Pharmaceuticals' short interest increasing or decreasing? Biodexa Pharmaceuticals saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 18,000 shares, a decrease of 95.1% from the previous total of 364,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Biodexa Pharmaceuticals' short interest compare to its competitors? 0.49% of Biodexa Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Biodexa Pharmaceuticals: Pliant Therapeutics, Inc. (5.81%), Anixa Biosciences Inc (1.37%), Oncolytics Biotech Inc. (2.51%), Zentalis Pharmaceuticals, Inc. (6.66%), Surrozen, Inc. (1.73%), Scilex Holding Company (8.76%), TScan Therapeutics, Inc. (3.75%), Adagene Inc. Sponsored ADR (0.16%), Quince Therapeutics, Inc. (2.16%), Immunic, Inc. (10.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Biodexa Pharmaceuticals stock? Short selling BDRX is an investing strategy that aims to generate trading profit from Biodexa Pharmaceuticals as its price is falling. BDRX shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Biodexa Pharmaceuticals? A short squeeze for Biodexa Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BDRX, which in turn drives the price of the stock up even further. How often is Biodexa Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BDRX, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Pliant Therapeutics Short Interest Data Anixa Biosciences Short Interest Data Oncolytics Biotech Short Interest Data Zentalis Pharmaceuticals Short Interest Data Surrozen Short Interest Data Scilex Short Interest Data TScan Therapeutics Short Interest Data Adagene Short Interest Data Quince Therapeutics Short Interest Data Immunic Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BDRX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access